Literature DB >> 2995556

Differences in humoral immunogenicity between herpes simplex virus types 1 and 2.

P Kampe, A Knoblich, M Dietrich, D Falke.   

Abstract

Infection of NMRI mice with increasing doses of six different strains of herpes simplex virus type 1 (HSV-1) induced increasing levels of neutralizing antibodies. In contrast, three strains of HSV-2, irrespective of the dose, induced only marginal antibody responses. Only strain HG 52 (HSV-2) at high doses of infection stimulated antibody formation. The virus content of some organs in 6- to 8-week-old mice appeared to be lower after HSV-2 than after HSV-1 infection. Application of immune-modulating drugs [silica or poly(I) X poly(C) coupled via L-lysine to CM-cellulose] resulted in little augmentation of antibody formation if compared to HSV-1 infection. Secondary infections with HSV-1 or HSV-2 after a primary dose of HSV-1 were followed by a marked booster response. In contrast, a primary infection with HSV-2 suppressed secondary responses of HSV-1 and HSV-2, thus indicating fundamental differences between the antibody-stimulating potency of HSV-1 and HSV-2 strains.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2995556     DOI: 10.1099/0022-1317-66-10-2215

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  7 in total

1.  The region 0.7615-0.796 m.u. of the HSV-1 genome determines suppression of humoral antibody formation against herpes simplex virus.

Authors:  K Wollert; T el Ansari; A Rösen-Wolff; D Falke
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

2.  Suppression of humoral antibody formation against sheep red blood cells by infections with HSV-2 and the influence of mouse cytomegalovirus. Brief report.

Authors:  S Nick; B Metzger; S Jonsić; D Falke
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

3.  Herpes simplex virus type 1 and 2 in the adrenal glands: replication and histopathology.

Authors:  D Potratz; B Brake; H P Dienes; T F Schulz; M Hosp; M P Dierich; D Falke
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

4.  Development of a glycoprotein D-expressing dominant-negative and replication-defective herpes simplex virus 2 (HSV-2) recombinant viral vaccine against HSV-2 infection in mice.

Authors:  Natalie V Akhrameyeva; Pengwei Zhang; Nao Sugiyama; Samuel M Behar; Feng Yao
Journal:  J Virol       Date:  2011-03-09       Impact factor: 5.103

5.  A vaccinia virus--herpes simplex virus (HSV) glycoprotein B1 recombinant or an HSV vaccine overcome the HSV type 2 induced humoral immunosuppression and protect against vaginal challenge in BALB/c mice.

Authors:  M Fleck; J Podlech; K Weise; D Falke
Journal:  Med Microbiol Immunol       Date:  1994-05       Impact factor: 3.402

6.  Suppression of humoral immune response against herpes simplex virus induced by defective strains, ts- and TK- mutants.

Authors:  B Metzger; J Podlech; S Müller; D Falke
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

7.  Asymptomatic vaginal herpes simplex virus infections in mice: virology and pathohistology.

Authors:  J Podlech; F Hengerer; M Fleck; K Eray
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.